The new board is comprised of Mark Wilcox, MD, who will serve as chair; Curtis Donskey, MD; Ciarán Kelly, MD; and Tom Louie, MD. Synthetic Biologics plans to initiate phase Ia and Ib clinical trials to evaluate SYN-004 in the second half of 2014.
“SYN-004 has the potential to have a significant impact on mitigating this urgent public health threat, and I look forward to working with the other advisory board members to help the company move this promising program forward as expeditiously and strategically as possible,” said Dr. Wilcox in a news release.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
